Kayothera
  • Science
  • Team
  • Investors
  • News
  • Contact
Select Page
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Sep 18, 2023 | News, Press Release

 Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies  Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

Jul 19, 2023 | News, Press Release

New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding  Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Kayothera, Inc. and Columbia University Announce Publication in Nature Communications Detailing Novel Therapeutic Strategy for Type 2 Diabetes

Feb 2, 2023 | News, Press Release

Seattle, WA — February 02, 2023,  A paper published today in the peer-reviewed journal Nature Communications, co-authored by researchers from Columbia University, Kayothera, Inc., and Princeton University, describes a new therapeutic strategy for treatment of type 2...
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics

Mar 16, 2022 | News, Press Release

Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of...
Next Entries »

Categories

  • Events (2)
  • News (25)
  • Press Release (10)
  • Contact
    © 2026 KAYOTHERA® — All Rights Reserved